- Home
- CMC vs AXSM Comparison
CMC vs AXSM Comparison
Compare CMC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMC
- AXSM
- Stock Information
- Founded
- CMC 1915
- AXSM 2012
- Country
- CMC United States
- AXSM United States
- Employees
- CMC N/A
- AXSM N/A
- Industry
- CMC Steel/Iron Ore
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- CMC Industrials
- AXSM Health Care
- Exchange
- CMC Nasdaq
- AXSM Nasdaq
- Market Cap
- CMC 4.9B
- AXSM 5.1B
- IPO Year
- CMC 1987
- AXSM 2015
- Fundamental
- Price
- CMC $46.11
- AXSM $107.76
- Analyst Decision
- CMC Buy
- AXSM Strong Buy
- Analyst Count
- CMC 7
- AXSM 15
- Target Price
- CMC $60.33
- AXSM $170.20
- AVG Volume (30 Days)
- CMC 805.3K
- AXSM 655.3K
- Earning Date
- CMC 06-20-2025
- AXSM 05-05-2025
- Dividend Yield
- CMC 1.56%
- AXSM N/A
- EPS Growth
- CMC N/A
- AXSM N/A
- EPS
- CMC 0.63
- AXSM N/A
- Revenue
- CMC $7,738,612,000.00
- AXSM $432,157,000.00
- Revenue This Year
- CMC N/A
- AXSM $63.52
- Revenue Next Year
- CMC $8.41
- AXSM $63.32
- P/E Ratio
- CMC $73.02
- AXSM N/A
- Revenue Growth
- CMC N/A
- AXSM 72.16
- 52 Week Low
- CMC $37.92
- AXSM $64.11
- 52 Week High
- CMC $64.53
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- CMC 57.28
- AXSM 46.37
- Support Level
- CMC $44.67
- AXSM $103.15
- Resistance Level
- CMC $46.61
- AXSM $120.00
- Average True Range (ATR)
- CMC 1.23
- AXSM 3.51
- MACD
- CMC 0.38
- AXSM 0.66
- Stochastic Oscillator
- CMC 83.84
- AXSM 29.45
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.